Tech Company Financing Transactions
Vtesse Funding Round
On 1/8/2015, Vtesse announced $25 million in Series A funding from New Enterprise Associates, Alexandria Venture Investments and Bay City Capital.
Transaction Overview
Company Name
Announced On
1/8/2015
Transaction Type
Venture Equity
Amount
$25,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to conduct a clinical program for VTS-270 (a formulation of (2-hydroxypropyl)-beta-cyclodextrin) for NPC, and to discover and pre-clinically evaluate additional novel drugs for NPC and other LSDs.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
910 Clopper Road 220S
Gaithersburg, MD 20878
USA
Gaithersburg, MD 20878
USA
Phone
Website
Email Address
Overview
The company has also established a Cooperative Research and Development Agreement (CRADA) with the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Center for Advancing Translational Sciences (NCATS), each a component of the National Institutes of Health (NIH).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Ben Machielse
VP - Bus. Development
Ravi Rao
VP - Operations
Allan Darling
VP - Regulatory Affairs
Kevin Johnson
Browse more venture capital transactions:
Prev: 1/8/2015: TodayTix venture capital transaction
Next: 1/8/2015: Dato venture capital transaction
Share this article
Where The Data Comes From
We report on funding rounds that are announced publicly. VC transactions on this site are sourced from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs